Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Capital Markets Day

On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an in...
Read more

Oasmia Pharmaceutical AB (publ)

Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base
Read more

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer.
Read more
To news archive